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Abstract At home injectable chemotherapy for patients receiv-
ing treatment for hematological diseases is still in debate. Given
the expense of new innovative medicines, at home treatment has
been proposed as a suitable option for improving patient quality
of life and decreasing treatment costs. We decided to assess the
cost of bortezomib administration in France among multiple
myeloma patients from an economic standpoint. Patients in this
study were treated within a regional hematological network
combining outpatient hospital care and Hospital care at Home
administration. To make the cost comparison, our team simulat-
ed outpatient hospital care expenses. Fifty-four consecutive mul-
tiple myeloma patients who received at least one injection of
bortezomib in Hospital care at Home from January 2009 to
December 2011 were included in the study. The median number
of injections was 12 (range 1–44) at home and 6 (range 0–30) in
the outpatient care unit.When comparedwith the cost simulation
of outpatient hospital care alone, bortezomib administration with
combined care was significantly less expensive for the National
Health Insurance (NHI) budget. The mean total cost per patient
and per injection was 954.20 € for combined outpatient and
Hospital care at Home vs 1143.42 € for outpatient hospital care
alone. This resulted in an estimated 16.5 % cost saving
(Wilcoxon signed-rank test, p < 0.0001). The greatest savings
were observed in administration costs (37.5 % less) and trans-
portation costs (68.1 % less). This study reflects results for a
regionally implemented program for multiple myeloma patients
treated with bortezomib in routine practice in a large rural area.
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Cost analysis . Bortezomib .Multiple myeloma . Care
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Introduction
Multiple myeloma is a clonal malignancy of plasma cells which
mainly affects an elderly population. In France, the median age
at death is 76 years old for males and 78 years old for females.
Article summary
This study is a comparison of the cost of bortezomib chemotherapy in
patients with multiple myeloma treated by a combination care in
outpatient unit and hospital care at home versus outpatient unit alone. The
combined management is significantly less expensive.
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In 2013, 10,659 patients were treated for multiple myeloma
with chemotherapy (+23.2 % compared with 2011) [1, 2].
Hematology departments in France are the third leading dis-
pensers of chemotherapy, accounting for 17.8 % of all sessions
administered [3]. With the development of oral chemotherapy,
treatment dispensation at home has been developed in the last
decade and subsequently for parenteral administration.
Two studies of home injectable chemotherapy have been
led in France for solid tumors [4] as well as for malignant
hemopathies. There was a recent study published by the team
in Nantes on cost benefits of bortezomib administration at
home for the multiple myeloma patients [5].
In France and in many European countries, the concept of
Hospital care at Home (HaH) has developed steadily over
several decades allowing at home treatment management for
patients. Based on the American model of Home Care, the
first French HaH structure was created in 1957 at the Public
Service - Paris Hospitals (Assistance Publique - Hôpitaux de
Paris (AP-HP)). HaH has been legally recognized in France
since 1970. In 1991, it became an alternative to hospitalization
and since 2009 has served as a form of outpatient hospitaliza-
tion itself. Themission of HaH is to provide adaptive care with
strong communication between providers for a limited amount
of time to patients benefiting from treatment at home. Due to
its evolution, HaH in France also refers to the structure itself
that is administering home care. It can be thought of as an
establishment independent of the hospital that provides both
Outpatient Department services and home care including in-
jectable chemotherapy sessions as one of its services. In
2011, there were over 11,000 beds available in France with
this type of supportive care [6].
Limousin is a French region covering an area of
17,000 km2 and is characterized by low population density
and the oldest population in France. There is one university
hospital and two local state-run hospitals each with a hema-
tology department. In 1994, these three hospitals set up a
network which was later organized in 1999 with a medical
coordinator. The HEMATOLIM network was officially
established in 2007 to adhere to the national BCancer Plan^
that outlines cancer care organization in France.
In 2009, a regional organization within the HEMATOLIM
network, externalization and securitization of injectable che-
motherapy at home for malignant hematological diseases
(ESCADHEM), was set up. This organization includes the
three previously mentioned hospitals, four HaH structures,
and three central pharmacies with an integrated preparation
unit for cancer treatments (Fig. 1). Both written procedures
and risk management processes for at home chemotherapy
administration were established and validated (Fig. 2).
In France, the decision to offer chemotherapy as a thera-
peutic option is made in a multidisciplinary meeting of spe-
cialists. The patient is informed about this option at a special
appointment (informational consultation). When the decision
to treat with bortezomib has been made and the patient profile
corresponds with the eligibility criteria, the ESCADHEM pro-
gram is proposed as part of the treatment option. A document
explaining at home chemotherapy administered by the HaH is
given to the patient during the informational consultation. To
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be cared for by ESCADHEM, three standard criteria must be
met: (1) a supportive family environment and the patient’s
consent; (2) a signed agreement between the general practi-
tioner, the HaH structure, and the visiting nurse; and (3) the
first chemotherapy cycle and D1 injection of subsequent cy-
cles are administered at the hospital.
Chemotherapy at home begins with the medical prescription
written by the hematologist at one of the region’s three hospi-
tals. The patient must then pass a hematology exam to insure
that the patient is fit to receive the prescribed treatment. Then,
the chemotherapy preparation starts in the hospital pharmacy in
accordance with regulations using specific software. Next, the
treatment is prepared and delivered to the HaH. The HaH must
insure (1) chemotherapy drugs prepared for transportation, (2)
reception and administration of the treatment in the patient’s
home, and (3) patient supervision at home by the family doctor
and/or the HaH’s coordinating doctor or the HaH nurse or the
floating nurse. The follow-up document and treatment tracking
and the patient’s tolerance are given to the hospital pharmacy
and to the hematologist by the HaH coordinating doctor; (4)
waste collection is conducted according to regulation (Fig. 2).
When ESCADHEM was in its developmental stages, three
drugs were chosen for externalization according to their in-use
stability and ease as well as frequency of administration:
bortezomib, azacitidine, and, less frequently, alemtuzumab.
This decision was made due to the facility and frequent ad-
ministration of these drugs. Their externalization avoids mul-
tiple visits to the outpatient care unit. These visits often present
long waiting times and a significant amount of time in transit
for patients living far from the hospital.
Bortezomib is indicated as monotherapy for the treatment of
progressive multiple myeloma in adult patients who have re-
ceived at least one prior therapy and who have already under-
gone or do not meet the requirements for bone marrow trans-
plantation. It is also indicated in combination with melphalan
and prednisone for the treatment of adult patients with previous-
ly untreated multiple myeloma who are not eligible for high-
dose chemotherapy with bone marrow transplantation.
Bortezomib has a 3-week treatment cycle. The recommended
starting dose [7] is 1.3 mg/m2 body surface area to be adminis-
tered via intravenous (IV) or subcutaneous (SC) [8] injection
twice weekly on days 1, 4, 8, and 11, followed by a 10-day rest
period on days 12–21. There is a 72-h wait time between con-
secutive doses of bortezomib. This proteasome inhibitor may be
combined with other alkylant molecules such as melphalan or
cyclophosphamide and corticosteroids. The frequency of injec-
tions may be weekly (instead of twice weekly) under certain
protocols with cycles of 4, 5, or 6 weeks (instead of 3 weeks)
[9–11]. Doses can be withheld or adjustments at 1 and 0.7 mg/
m2 are planned depending on toxicities. The chemical and phys-
ical in-use stability of the reconstituted solution has been dem-
onstrated to be valid for at least 8 h at 25 °C stored in the original
vial and/or syringe. The total storage time for the reconstituted
medicinal product should not exceed 8 h prior to administration.
The aim of this study was to assess the cost of a
combined treatment of Outpatient Hospital (OH) care
and at home chemotherapy with injectable bortezomib
over three consecutive years in the rural Limousin re-
gion of France. In comparison, cost assessment was cal-
culated as if patients had been treated in OH care alone.
1
• Authorized cancer treatment hospital: Paent care provision.
2
• Muldisciplinary cancer meeng  followed by paent informaon consultaon: Therapeuc proposal.
3
• ESCADHEM inclusion plan via HEMATOLIM NETWORK coordinaon: Paent consent obtained, eligibility criteria analysed
(eg. supporve family environment).
4
• Paent informed consent in accordance with the general condions of the HaH chosen by the paent. The paent’s house 
must be in a geographical area covered by the HaH. 
5
• Outpaent unit: Cycle 1 and then Day 1 of each subsequent therapy cycle. 
6
• Licensed hospital pharmacy : Preparaon of treatment according to the hematologists prescripon.  HaH: Transportaon 
and Receving treatment at paent’s home. 
7
• Home nurse: Recepon and administraon of injectable bortezomib at home. HaH: Waste collecon. 
8
• Paent monitoring in cooperaon with general praconers and / or HaH physician coordinator.
9
• Quality assessment, procedure updates and risk management procedures established.
ESCADHEM: externalizaon and securizaon of injectable chemotherapy at home for malignant hematological diseases.
HaH: Hospital care at Home.
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Fig. 2 Organizing injectable chemotherapy via Hospital care at Home with ESCADHEM
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Patients and methods
Inclusion criteria In 2012, all ESCADHEM patients consec-
utively treated with bortezomib injection for multiple myelo-
ma starting in January 2009 and ending in December 2011
were contacted to participate in this retrospective study. Of
the 88 patients who received at least one bortezomib injection,
54 patients gave their consent and were able to declare their
mode of transport. All patient data were collected from elec-
tronic and paper hospital files.
The first cycle of bortezomib and the first injection of each
cycle were administered via OH care. The decision to admin-
ister each subsequent injection at home or at the outpatient
care unit was determined by the healthcare professionals.
Cost assessment In France, there are several organizations for
the administration of anticancer chemotherapy which include
OH care and HaH. The cost for the NHI is determined by the
health authorities [12, 13] in which 100 % of cancer medical
costs are funded by the government (national fees). There is
no extra charge paid by the patient. The average cost of
bortezomib administration corresponds to the cost of patient
receiving an anticancer chemotherapy and is dependent on the
administration route, OH, or an OH/HaH combination. For
our study, only direct costs were recorded.
When determining OH cost, the patient is classified in the
diagnosis-related group (DRG) so-called GHM in French,
which means homogeneous group of patients, labelled
BChemotherapy for tumor, in sessions^ referred to specific
coding of care 28Z07Z which indicates treatment cost to the
NHI. In 2012, our patient population corresponded to an OH
Bhospital stay group^ (GHS) with a cost of 397.58 € in a
public health institution. This GHS covers the following
items: cost of medical and non-medical staff, logistic and gen-
eral management, medical logistics, and the direct costs ex-
cluding expensive drugs. Expensive drugs, such as
bortezomib, are registered outside of the GHS rate, and the
NHI pays the hospital directly for the medicine. Similarly,
direct non-medical costs such as transportation are not includ-
ed in the GHS and are covered by the NHI according to the
mode of transport (ambulance, taxi, car, public transport, etc.)
and distance travelled. Distance was calculated using Google
Maps. Costs associated with exclusive OH care management
were estimated thanks to a model based on the same method-
ology as the combined OH plus HaH management.
HaH cost was evaluated according to the corresponding
dedicated home DRG, homogeneous tariff group so-called
in France GHT, which is a daily cost [14]. The GHT is based
on a score calculated with four criteria: the primary mode of
care (i.e., anticancer chemotherapy), secondary associated
care (none of the patients), Karnofsky index, and duration of
care. Finally, the cost for HaH is achieved by multiplying the
length of chemotherapy administration (1 day in the present
study) by the daily cost of GHT (Table 1). GHTcosts, paid by
the NHI, cover the cost of medical and non-medical staff,
logistic and general management, and medical logistics (i.e.,
transportation of bortezomib). For whatever the type of care,
HaH or OH, the NHI cost is obtained by adding the costs of
transportation and bortezomib to the HaH or OH care cost.
Statistics Descriptive analysis was reported with means
and standard deviations, medians, and ranges. Wilcoxon
rank sum and chi-squared tests were used to determine
if there was any significant difference in costs between
the combination care of OH/HaH and OH care alone.
The statistical analysis was performed with SAS 9.2 soft-
ware (Cary, North Carolina, USA).
Approval of the local ethics committee was obtained before
the beginning of the study.
Results
Between the January 1, 2009 and December 31, 2011, 88
patients with multiple myeloma received at least one injection
of bortezomib in HaH. The cohort of the 54 patients included
28males and 26 females with a median age of 65 years (range,
41–87) and more than a third were >70 years old (Suppl. table:
Patient characteristics). The median performance status
assessed by Karnofsky index was 70 (range, 50–100). A ma-
jority (57 %) of patients had Karnofsky indices <70 %.
Twenty-nine patients (54 %) were on first-line treatment, 14
(26 %) in second line, and 11 (20 %) received more than 2
lines of treatment. Bortezomib was combined with other mol-
ecules: corticosteroids only (n = 26), melphalan and steroids
(n = 16), cyclophosphamide and steroids (n = 14), thalidomide
and steroids (n = 7), lenalidomide and steroids (n = 3), and
liposomal doxorubicin plus steroids (n = 1). Twenty patients
Table 1 Daily cost of
home DRG GHT Daily cost
GHT 6 133.57 €
GHT 9 181.57 €
GHT 10 198.46 €
GHT 12 230.49 €
GHT 13 246.51 €
Home diagnosis-related group (DRG) cor-
responding in France to GHTwhich means
homogeneous tariff group is a daily cost
based on a score calculated with four
criteria: the primary mode of care (i.e., an-
ticancer chemotherapy), secondary associ-
ated care (none of the patients), Karnofsky
index, and duration of care
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overall received intensive therapywith autologous hematopoi-
etic stem cell.
A total of 1292 infusions were administered: 900 injections
were performed via HaH and 392 injections were given via
OH care. The range of injections received at home by patients
was 1–44 with a median of 12 injections. One third of patients
received 20 or more injections (Suppl. Fig. 3). During the
study period, there were no major complications related to
bortezomib administration at home. The total duration of
HaH management lasted from less than 1 month to more than
2 years with a median of 3.2 months and a mean of
5.7 ± 5.9 months. A median of six injections was received
by the patients (range, 0–30) at the outpatient unit and 46 %
of patients received five or fewer injections. Some patients did
not receive the three injections of a given cycle at home.
With regards to transport, the majority of patients used a
light health vehicle (50 %) or their own car (31.5 %) and only
four patients (7.4 %) were transported by ambulance—the
most expensive transport (Table 2). The median home–hospi-
tal distance was 34.2 km (range, 2–140), and 44 % of the
patients lived less than 20 km from the prescription site.
The mean total cost per patient and per injection was
954.20 € for combined management OH/HaH and 1143.42 €
for OH alone (Wilcoxon signed-rank test, p < 0.0001)
(Table 3). The OH/HaH combination produced a cost reduc-
tion of 16.5% compared with the model used to simulate daily
hospital care. Differences were mainly due to the mean cost of
administration (255.54 € vs 397.57 €) and the cost of patient
transportation. The transportation cost accounted for 2.3 % of
the total cost per injection in combined OH/HaH manage-
ment, whereas it reached more than 6 % of the total cost for
the administration of treatment via OH care alone. The empir-
ical distribution of the total costs and the total cost distribution
are shown in Suppl. Figs. 4, 5, and 6.
Discussion
This study showed that administration of bortezomib with
combined care is less costly for the NHI budget than an
administration of the drug using OH care alone. Time and cost
benefits are the main advantages to be highlighted from this
new way of care for cancer patients.
The strong point of our study is that it demonstrates a sig-
nificant savings of a combination of HaH and OH care with
the aim to improve patient comfort, especially for elderly and
frailer patients. Although an increasing number of anticancer
molecules are available in oral form, we will continue to treat
patients with injectable molecules (IV or SC) requiring the
implementation of organization for the externalization of che-
motherapy in a home-safe way. There are currently new drug
chemotherapy treatments with similar administration profiles
that could be externalized.
With the administration of two thirds of injections at home,
a cost savings of 16.5 % might be achieved, representing an
economy of 189 € per injection of bortezomib. Savings have
been made in the administration category (37.5 % less) and in
the transport category (68.1 % less). This study showed that
the cost of patient care in France is dependent on various
methods of treatment (combined OH and HaH vs OH alone)
but also revealed the impact of transportation cost in the total
treatment cost.
There are a couple limitations to our study. One limitation
is the retrospective nature of data collection that may have
induced minor difficulties in terms of finding accurate patient
records; however, this limitation is compensated for by the use
of electronic files that can easily be accessed and updated.
Another limitation is that this study was performed in one
region. While one might extrapolate findings to other regions,
such extrapolations need to be adapted to the specific care
provided by medical institutions in those regions.
Other teams have described experiences similar to ours. In
one case, bortezomib administration in myeloma patients was
performed at home from the first dose without significant
problems [15]. Given the current national guidelines
established in 2003, we have favored the first day of each
cycle of therapy with bortezomib at the outpatient care unit
[16].
The Nantes team [5] has recently published the results of a
medico-economic study/satisfaction survey of bortezomib
Table 2 Transportation
characteristics from home to
outpatient hospital care unit
Transportation modalities Average distance per
patient (km)
Average cost per
patient (km)
Number of
patients
%
Light service vehicle 66.71 77.26 27 50.0
Own car with reimbursement of
cost request
90.2 27.66 9 16.7
Own car without reimbursement
of cost request
67.0 0 8 14.8
Taxi 71.44 123.06 5 9.3
Ambulance 45.11 198.32 4 7.4
Other 6 2.6 1 1.9
Total 54 100
Support Care Cancer (2016) 24:5007–5014 5011
home administration managed by a territorial network funded
for home care. Their results are similar to ours with 20 %
savings between outpatient care and home administration that
is less expensive. The difference with our experience is that
bortezomib is managed by a territorial network and provided
from the pharmacy directly to the nurse in charge of home
administration without depending on a HaH structure as is
the case in Limousin.
Savings for chemotherapy administered at home has also
been demonstrated in solid tumors like colorectal, non-small
cell lung cancer with a decrease in expenses of up to 53 % for
intensive chemotherapies mainly administered for hematolog-
ical malignancies [4, 5, 17].
One study had an innovative idea for bringing treatment to
patients. A hospital in South Wales delivers chemotherapy as
close as possible to the patient’s home using amobile unit with
a bus [18].
In one nursing study [15], from the patient and family point
of view, the advantages of chemotherapy injection at home are
numerous: being in one’s own environment leading to less
disturbances to daily life, less time in transit and less fatigue,
and the ability to continue a professional activity. All these
aspects of treatment management at home have been shown to
improve or maintain quality of life [19–22].
In 2014, we conducted a satisfaction survey (unpublished
data) with patients who received treatment in HaH structures
via ESCADHEM in 2013. Of the 84 patients addressed by the
survey, 61 (73 %) responded including 34 patients with mul-
tiple myeloma treated by bortezomib. The overall satisfaction
rate was 95 %. All surveyed patients (100 %) were willing to
recommend this mode of care to close relations. The four
HaHs participating in ESCADHEM organization were rated
8.7 out of 10. Of the benefits reported by the patients, 55
(90%) confirmed a sense of security, 54 (88%) reported home
environment, 54 (88 %) mentioned less time in transit, 52
(85 %) appreciated no hospital wait, and 46 (75 %) patients
mentioned continuing daily life. Of the patients surveyed, 54
(88 %) reported no disadvantage while 3 (5 %) feel they are a
burden to their family, and 4 (6 %) mentioned poor commu-
nication with the hospital team. These results concur with
those of the satisfaction survey conducted by the team from
Nantes [5] which shows that home bortezomib administration
is preferred by patients.
In the last decade, interest in developing administration of
chemotherapy at home has increased with the aim of increas-
ing patient quality of life. While this may be the case, one of
the side results has been an alleviation of overcrowding in
inpatient oncology, hematology, and outpatient units. The ex-
ternalization of treatment theoretically induces a loss of re-
sources for hospitals, and this has proven an obstacle in some
hospitals. In France, many hematology departments are
overloaded. With this organization, patient care is improved
and a wider range of patients are admitted. In the end, as in our
department, there is an increase in the number of outpatient
hospital venues.
In January 2015, the French Health Authorities
[Haute Autorité de Santé (HAS)] [23] published an on-
line report supporting the development of chemotherapy
via HaH structures. This project in which the network
HEMATOLIM [24] has collaborated indicates that in
2016, the administration of injectable chemotherapy at
home still remains an activity underdeveloped and un-
evenly distributed throughout France. The tariff model
of participating institutions is often a disincentive to the
development of home chemotherapy and thus slows the
development of this type of health care organization.
However, the report concludes that HaH is a relevant
modality of patient care that should be developed in
order to allow the practice of some injectable chemo-
therapy molecules in the home environment.
Table 3 Cost per patient
Criteria Exclusive
outpatient care
Outpatient and hospital at
home cares
Drug Cost of the drug per mg, mean (SD), Euros 320.75 (0) 320.75 (0)
Dosage of the drug, mean (SD), mg 2.11 (0.33) 2.11 (0.33)
Administration Cost of administration, mean (SD), Euros 397.57 (0) 255.54 (48.03)
Number of drug injections in HO, mean
(SD)
16.67 (10.90)
Number of drug injection at outpatient care
unit, mean (SD)
23.93 (13.13) 7.26 (5.51)
Transport Cost of transportation, per km per
injection, mean (SD), Euros
1.01 (1.77) 0.32 (0.56)
Distance home-hospital (round trip), mean
(SD)
68.38 (67.54) 68.38 (67.54)
Total cost per patient and per injection,
Euros
1143.42 € 954.20 €
Costs were calculated with current Euro to 2012
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The cost of chemotherapy in HaH vs using OH de-
pends on multiple parameters (institution status, coding
of care, duration of care, Karnofsky index). However,
there is no single answer to suggest that HaH is always
the less costly option compared to OH. For example,
the administration of injectable chemotherapy at home
appears more costly than OH for treatment with
bortezomib D1, D4, D8, and D11 if the patient stays
in HaH between injections and if the D-1 is the balance
sheet encoded by the HaH. This analysis done by HAS
has shown that HaH sometimes cannot be less costly for
health insurance than the OH alternative. The parameter
impacting the results is the protocol procedures, espe-
cially the interval between injections. According to the
report, the cost associated with HaH is generally lower
than the conventional OH. However, this finding is re-
lated to the pricing methods used by HaH (per day vs
per sequence) and is protocol dependent.
Conclusion
One of the aims of hematological malignancy care is to deliver
innovative drugs at home, especially for an aging patient pop-
ulation. This treatment management needs to be coordinated
by a regional hematological care network with processes val-
idated for ensuring safe patient conditions. Our study of at
home bortezomib injections with combination HaH/OH dem-
onstrated a significant cost savings compared with OH care
alone. This indicates that exclusive HaH or exclusive OH care
is not the most economic approach. A combination of the two
could strike an economic balance that ensures patient safety
and quality of life.
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